COURAGE patients who crossed branch.

This editorial comment was written by SOLACI.ORG and is based on an original article by Medscape which can be accessed free of charge at the bottom of this page.

COURAGE patients (Patients in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) who crossed from the optimal medical treatment branch to the revascularization branch within one year of randomization were more likely to present significant angina that affected their quality of life and were also more likely to be dissatisfied with the treatment and the health system in which they found themselves. These results were recently published in Circulation: Cardiovascular Quality and Outcomes.

No less important is the fact that crossing from optimal medical treatment to the revascularization branch was not associated with an increased risk of death or MI compared with patients who received early revascularization, although typically the symptoms and quality of life were worse in the optimal medical therapy group during that first year. With that information the author of the article, (Dr John Spertus), believes that we are better able to identify patients who require immediate revascularization which do not change hard end points. This is something that interventionists have argued for a long time. COURAGE has been criticized for allowing this crossover, (one third of the patients were crossed to follow up), and maybe this is the reason that no differences are observed in the hard end points. But critics say it is probable that critical patients are those who crossed within the first year, these were the ones that really could not be treated with medication only, the rest could be explained by the progression of the disease.

Of the 1,168 patients randomized to medical treatment, “only” 16% were crossed within the first year. The most important predictors of early revascularization were health status and the health system where they were assisted. For example, for patients treated in Canada were 37% more likely for early revascularization than those treated under the Veteran’s health system. Probably in the first system patients were more likely to express their symptoms and to make it clear to doctors that, despite optimal medical treatment, they were not satisfied and continued to feel limited.

This work does not have enough power to reach definitive conclusions but it seems clear that there are no differences in hard points such as death or myocardial infarction between the two strategies. However, we must be aware of the symptoms that patients report to provide adequate revascularization when (relatively common) medical treatment is not enough.

SOLACI.ORG

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...